PRALUENT® Market Access Team
Sanofi US and Regeneron Pharmaceuticals, Inc.
Agency Partner: Entrée Health
Tiffany Stout, Senior Director,
Cardiovascular Value & Access, Sanofi US
Bennett M. Smith, Senior Director, U.S. and Global Market Access, Regeneron Pharmaceuticals, Inc.
Kati Sadiwnyk, Director, Cardiovascular Value & Access, Sanofi US
Stephen Dressel, Associate Director, Market Access, Regeneron Pharmaceuticals, Inc.
The Alliance Dream Team
Teamwork isn’t always easy. And that is true even if you are talking about a team within one organization. The PRALUENT® (alirocumab) Marketing Team came together as part of a Sanofi US and Regeneron Pharmaceuticals, Inc. co-promote, known as The Alliance, to work in a challenging marketplace on a valuable, complex product.
The PCSK9 inhibitor class is heavily managed by payers that restrict access to many patients prescribed them. If that wasn’t complicated enough, The Alliance must understand, acknowledge, and work within each organization’s objectives and culture, as well as work seamlessly across vendors and each other’s medical, legal, and regulatory review teams.
Even with the many challenges laid before them, the PRALUENT Market Access team hit the ground running and has since made PRALUENT the most covered PCSK9 inhibitor on the market. PRALUENT is now at parity or better for more than 9 out of 10 insured patients across Commercial and Medicare. And the team hasn’t slowed down yet. In 2018, total Commercial lives covered has already increased by 33 million and total Medicare lives covered has increased by one million.
If you doubt the great things this team can achieve together, then keep your eyes open as it continues to secure a position for PRALUENT and improve access for appropriate patients. If past accomplishments are any indication of what the future holds, then 2018 will be impressive, to say the least.